{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Octanoic+Acid&page=2", "query": { "intervention": "Octanoic Acid", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Octanoic+Acid&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-21T06:34:30.862Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02314026", "title": "BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Alcoholic Steatohepatitis" ], "interventions": [ { "name": "Suspected NASH BreathID test with 13C-Octanoate", "type": "DEVICE" }, { "name": "Suspected NASH Breath test with 13C Methacetin", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Meridian Bioscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2015-03", "completion_date": "2017-06", "has_results": true, "last_update_posted_date": "2022-12-20", "last_synced_at": "2026-09-21T06:34:30.862Z", "location_count": 8, "location_summary": "Chicago, Illinois • Forts Sam Houston, Texas • Houston, Texas + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Forts Sam Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02314026" }, { "nct_id": "NCT00220779", "title": "Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis, Relapsing-Remitting" ], "interventions": [ { "name": "Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified", "type": "DRUG" }, { "name": "Albumin (Human) 25%, United States Pharmacopeia (USP)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Grifols Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 128, "start_date": "2002-12", "completion_date": "2005-02", "has_results": true, "last_update_posted_date": "2016-04-27", "last_synced_at": "2026-09-21T06:34:30.862Z", "location_count": 6, "location_summary": "Phoenix, Arizona • Tucson, Arizona • New York, New York + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "New York", "state": "New York" }, { "city": "Stony Brook", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00220779" }, { "nct_id": "NCT01835041", "title": "CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acinar Cell Adenocarcinoma of the Pancreas", "Duct Cell Adenocarcinoma of the Pancreas", "Recurrent Pancreatic Cancer", "Stage IV Pancreatic Cancer" ], "interventions": [ { "name": "6,8-bis(benzylthio)octanoic acid", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2013-04", "completion_date": "2023-03-16", "has_results": false, "last_update_posted_date": "2023-07-12", "last_synced_at": "2026-09-21T06:34:30.862Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01835041" }, { "nct_id": "NCT01902381", "title": "CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Previously Treated Myelodysplastic Syndromes" ], "interventions": [ { "name": "6,8-bis(benzylthio)octanoic acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2013-08", "completion_date": "2018-11-26", "has_results": true, "last_update_posted_date": "2024-10-17", "last_synced_at": "2026-09-21T06:34:30.862Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01902381" }, { "nct_id": "NCT03420976", "title": "Novel Supplement-based Therapy for the Treatment of Small Intestinal Bacterial Overgrowth", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Small Intestinal Bacterial Overgrowth" ], "interventions": [ { "name": "Novel Supplement Based Therapy", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Atrium Innovations", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "84 Years", "sex": "ALL", "summary": "19 Years to 84 Years" }, "enrollment_count": 0, "start_date": "2017-12-07", "completion_date": "2019-02-01", "has_results": false, "last_update_posted_date": "2021-01-12", "last_synced_at": "2026-09-21T06:34:30.862Z", "location_count": 1, "location_summary": "Oxford, Ohio", "locations": [ { "city": "Oxford", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03420976" }, { "nct_id": "NCT02604810", "title": "Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Immunodeficiency" ], "interventions": [ { "name": "IGIV-C 10%", "type": "BIOLOGICAL" }, { "name": "IGSC 20%", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Grifols Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "2 Years to 75 Years" }, "enrollment_count": 53, "start_date": "2016-01", "completion_date": "2017-12", "has_results": true, "last_update_posted_date": "2019-10-04", "last_synced_at": "2026-09-21T06:34:30.862Z", "location_count": 20, "location_summary": "Los Angeles, California • Santa Monica, California • Denver, Colorado + 17 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "North Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02604810" }, { "nct_id": "NCT07540221", "title": "A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)" ], "interventions": [ { "name": "Gamunex-C", "type": "BIOLOGICAL" }, { "name": "Xembify", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Grifols Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2026-04-02", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-09-21T06:34:30.862Z", "location_count": 7, "location_summary": "Rancho Mirage, California • Coral Springs, Florida • Miami, Florida + 4 more", "locations": [ { "city": "Rancho Mirage", "state": "California" }, { "city": "Coral Springs", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Port Charlotte", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07540221" }, { "nct_id": "NCT02168907", "title": "CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-cell Adult Acute Lymphoblastic Leukemia", "B-cell Chronic Lymphocytic Leukemia", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Testicular Lymphoma", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "6,8-bis(benzylthio)octanoic acid", "type": "DRUG" }, { "name": "bendamustine hydrochloride", "type": "DRUG" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2014-12", "completion_date": "2015-02", "has_results": false, "last_update_posted_date": "2018-07-02", "last_synced_at": "2026-09-21T06:34:30.862Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02168907" }, { "nct_id": "NCT02014649", "title": "Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "20 mg laninamivir octanoate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "40 mg laninamivir octanoate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biota Scientific Management Pty Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "5 Years to 17 Years" }, "enrollment_count": 15, "start_date": "2013-11", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2025-01-13", "last_synced_at": "2026-09-21T06:34:30.862Z", "location_count": 28, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 21 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bellflower", "state": "California" }, { "city": "Canoga Park", "state": "California" }, { "city": "Lakewood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02014649" }, { "nct_id": "NCT01839981", "title": "CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acinar Cell Adenocarcinoma of the Pancreas", "Duct Cell Adenocarcinoma of the Pancreas", "Recurrent Pancreatic Cancer", "Stage III Pancreatic Cancer", "Stage IV Pancreatic Cancer" ], "interventions": [ { "name": "6,8-bis(benzylthio)octanoic acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2013-07", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2018-12-27", "last_synced_at": "2026-09-21T06:34:30.862Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01839981" } ] }